Latest Research Reports

The need for action: improving awareness and early diagnosis of SLE

The need for action: improving awareness and early diagnosis of SLE

Geographical variations in spondyloarthropathies prevalence related to HLA-B27 Prevalence

Geographical variations in spondyloarthropathies prevalence related to HLA-B27 Prevalence

Recent failures in Alzheimer’s Research and Development (R&D)

Recent failures in Alzheimer’s Research and Development (R&D)

Total Prevalent Cases of Dyslipidemia Expected to Grow Globally

Total Prevalent Cases of Dyslipidemia Expected to Grow Globally

C. difficile pipeline vaccines could offer an alternative to antibiotics

The incidence of Clostridium difficile has increased significantly over the last two decades, due in part to the emergence of new, hyper-virulent strains. In recent years it has surpassed MRSA...

C. difficile pipeline vaccines could offer an alternative to antibiotics

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

FDA approval of siliq for psoriasis – how will the drug perform in an already overcrowded market?

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

A large number of clinical trials evaluating inhibitors of the enzyme poly ADP ribose polymerase (PARP) in breast and ovarian cancers are either ongoing or completed....

Development of PARP inhibitors for ovarian and breast cancer is equally extensive

Targeted therapies will radically improve head and neck cancer treatment

Head and neck cancer (HNC) is the sixth most common cancer worldwide, and the majority of available treatments are highly toxic...

Targeted therapies will radically improve head and neck cancer treatment

FDA approves Eucrisa, first-in-class PDE4 inhibitor for atopic dermatitis

On December 14 2016, Pfizer announced the FDA approval of Eucrisa (crisaborole) ointment 2%, a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, for the treatment of mild to...

FDA approves Eucrisa, first-in-class PDE4 inhibitor for atopic dermatitis